These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 12120260)
1. Genome-based pharmacogenetics and the pharmaceutical industry. Roses AD Nat Rev Drug Discov; 2002 Jul; 1(7):541-9. PubMed ID: 12120260 [TBL] [Abstract][Full Text] [Related]
2. [Drug therapy at the beginning of the genomic era]. Stoica O; Braha E; Ungureanu G Rev Med Chir Soc Med Nat Iasi; 2002; 107(2):240-6. PubMed ID: 12638267 [TBL] [Abstract][Full Text] [Related]
3. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341 [TBL] [Abstract][Full Text] [Related]
4. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Nelson MR; Bacanu SA; Mosteller M; Li L; Bowman CE; Roses AD; Lai EH; Ehm MG Pharmacogenomics J; 2009 Feb; 9(1):23-33. PubMed ID: 18301416 [TBL] [Abstract][Full Text] [Related]
5. Evolution of pharmacogenomics. Somogy A Proc West Pharmacol Soc; 2008; 51():1-4. PubMed ID: 19544663 [TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics in solid organ transplantation: current status and future directions. de Jonge H; Kuypers DR Transplant Rev (Orlando); 2008 Jan; 22(1):6-20. PubMed ID: 18631854 [TBL] [Abstract][Full Text] [Related]
11. Global gene mining and the pharmaceutical industry. Knudsen LE Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):679-83. PubMed ID: 15979678 [TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics and the practice of medicine. Roses AD Nature; 2000 Jun; 405(6788):857-65. PubMed ID: 10866212 [TBL] [Abstract][Full Text] [Related]
13. SNPs and haplotypes: genetic markers for disease and drug response (review). Shastry BS Int J Mol Med; 2003 Mar; 11(3):379-82. PubMed ID: 12579344 [TBL] [Abstract][Full Text] [Related]
14. Interpreting P values in pharmacogenetic studies: a call for process and perspective. Maitland ML; Ratain MJ; Cox NJ J Clin Oncol; 2007 Oct; 25(29):4513-5. PubMed ID: 17925544 [No Abstract] [Full Text] [Related]
16. SNP market view: opportunities, technologies, and products. Wypgant M Biotechniques; 2002 Jun; Suppl():78-80, 82, 84 passim. PubMed ID: 12083402 [No Abstract] [Full Text] [Related]
17. Ontogeny and drug metabolism in newborns. Dotta A; Chukhlantseva N J Matern Fetal Neonatal Med; 2012 Oct; 25 Suppl 4():83-4. PubMed ID: 22958028 [TBL] [Abstract][Full Text] [Related]
18. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Zhou SF; Liu JP; Chowbay B Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967 [TBL] [Abstract][Full Text] [Related]
19. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
20. [Pharmacogenomics: the quest for individualized therapy]. López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]